Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Numinus Wellness Inc

Numinus Wellness Announces Q3 Results

Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX: NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.

Benzinga · Jul 15, 2022

Numinus To Provide Psychedelic-Assisted Therapy In This Western State

The mental health care company Numinus Wellness Inc.

Benzinga · Jun 23, 2022

Numinus Submits New Patent Application To UN Agency For Psilocybe & Novel Fungi Species

Numinus Wellness Inc.

Benzinga · Jun 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

New Acquisition: Numinus To Buy Common Shares Of Novamind Pending Canadian Supreme Court Approval

Numinus Wellness Inc.

Benzinga · Jun 9, 2022

Numinus' Ongoing Collaboration With Health Canada Spurs Mindspace Clinic Approval In Quebec

A longstanding commitment of Numinus Wellness Inc. (OTC: NUMIF) to collaborate with Health Canada to help shape protocols for the Special Access Program appears to be paying dividends.

Benzinga · May 24, 2022

Numinus Granted Canada's Special Access Program For Magic Mushrooms To Treat Life-Threatening Conditions

Numinus Wellness Inc (OTCQB: NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.

Benzinga · May 16, 2022

Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc.

In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action.

Benzinga · Apr 13, 2022

Read news from The Economist, FT, and more,
with one subscription

Numinus To Acquire Novamind For $20.74M In Stock

Numinus Wellness Inc. (TSX:NUMI)(OTCQX:NUMIF) and Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately CA$26.2 million…

Benzinga · Apr 12, 2022

Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS

Numinus Wellness Inc. (OTCQX:NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by…

Benzinga · Mar 30, 2022

Numinus Wellness Reveals 244.5% YoY Improvement In Q1 Revenue & Wider Loss

Numinus Wellness Inc (TSX: NUMI) (OTC: NUMIF) reported its fiscal first-quarter results Thursday for the three months ended Nov. 30, 2021.

Benzinga · Jan 21, 2022

Coverage From

Benzinga

People

Louis Reed

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.